The enzymatic conversion of CNS cholesterol to 24S-hydroxycholesterol, which readily crosses the blood-brain barrier, is the major pathway for brain cholesterol elimination and brain cholesterol homeostasis maintenance. The enzyme mediating this conversion has been characterized at the molecular level (CYP46) and is mainly located in neurons. Like other oxysterols, 24S-hydroxycholesterol is efficiently converted into normal bile acids or excreted in bile in its sulfated and glucuronidated form. Levels of 24S-hydroxycholesterol in the circulation decrease with age in infants and children. In adults, however, the levels appear to be stable. There is accumulating evidence pointing toward a potentially important link between cholesterol, β-amyloid, and Alzheimer's disease. Concentrations of 24S-hydroxycholesterol in plasma and cerebrospinal fluid (CSF) are significantly higher in Alzheimer’s disease and vascular demented patients at early stages of the disease compared to healthy subjects. Variations in genetic background, time of disease onset, and severity of dementia are potential sources of variance. Inhibitors of cholesterol biosynthesis, also termed statins, seem to have a reductive influence on the generation of the amyloid precursor protein, the neuronal secretion of β-amyloid, and on de novo cholesterol synthesis. Recent epidemiological studies indicate that the prevalence of diagnosed AD and vascular dementia is reduced among people taking statins for a longer period of time. High-dose simvastatin treatment (80 mg/day) in patients with hypercholesterolemia leads to a significant decrease in brain-specific serum 24S-hydroxycholesterol concentrations and indicates a diminished cholesterol metabolism in the brain. CSF levels of cholesterol and lathosterol, a cholesterol precursor considered to be an indicator for cholesterol neogenesis, were significantly decreased in statin-treated subjects compared to non-treated normo- and hypercholesterolemic subjects. Also, CSF concentrations of 24S-hydroxycholesterol were significantly lower in statin-treated patients compared to normocholesterolemic subjects. Treatment with high-dose simvastatin in normocholesterolemic Alzheimer patients for 26 weeks at early stages of the disease results in a significant decrease in Aβ-levels in cerebrospinal fluid. This decrease correlates with the reduction of 24S-hydroxycholesterol.
References
-
1
Babiker A, Diczfalusy U.
Transport of side-chain oxidized oxysterols in the human circulation.
Biochim Biophys Acta.
1998;
1392
333-339
-
2
Ball M -J.
Neuronal loss, neurofïbrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study.
Acta Neuropathol Berl.
1977;
37
111-118
-
3
Björkhem I, Andersson U, Ellis E, Alvelius G, Ellegard L, Diczfalusy U. et al .
From brain to bile. Evidence that conjugation and omega-hydroxylation are important for elimination of 24S-hydroxycholesterol (cerebrosterol) in humans.
J Biol Chem.
2001;
276
37 004-37 010
-
4
Björkhem I, Lütjohann D, Breuer O, Sakinis A, Wennmalm A.
Importance of a Novel Oxidative Mechanism for Elimination of Brain Cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18Ü2 techniques in vivo and in vitro.
J Biol Chem.
1997;
272
30 178-30 184
-
5
Björkhem I, Lütjohann D, Diczfalusy U, Stable L, Ahlborg G, Wahren J.
Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation.
J Lipid Res.
1998;
39
1594-1600
-
6
Björkhem I, Miettinen T, Reihner E, Ewerth S, Angelin B, Einarsson K.
Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver.
J Lipid Res.
1987;
28
1 137-1 143
-
7
Botti R -E, Triscari J, Pan H -Y, Zayat J.
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
Clin Neuropharmacol.
1991;
14
256-261
-
8
Bretillon L, Lütjohann D, Stable L, Widhe T, Bindl L, Eggertsen G. et al .
Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface.
J Lipid Res.
2000;
41
840-845
-
9
Dietschy J -M, Turley S -D.
Cholesterol metabolism in the brain.
Curr Opin Lipidol.
2001;
12
105-112
-
10
Dupuy A -M, Mas E, Ritchie K, Descomps B, Badiou S, Cristol J-P. et al .
The relationship between apolipoprotein E4 and lipid metabolism is impaired in Alzheimer’s disease.
Gerontology.
2001;
47
213-218
-
11
Fassbender K, Simons M, Bergmann C, Stroick M, Lütjohann D, Keller P. et al .
Simvastatin strongly reduces levels of Alzheimer’s disease beta - amyloid peptìdes Abeta 42 and Abeta 40 in vitro and in vivo.
Proc Natl Acad Sci USA..
2001;
98
5856-5861
-
12
Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S. et al .
Effects of statins on cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide.
Neurology.
2002;
59
1257-1258
-
13
Frears E -R, Stephens D -J, Walters C -E, Davies H, Austen B -M.
The role of cholesterol in the biosynthesis of beta-amyloid.
Neuroreport.
1999;
10
1699-1705
-
14
Galbete J -L, Martin T -R, Peressini E, Modena P, Bianchi R, Forloni G.
Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway.
Biochem J.
2000;
348
307-313
-
15
Hartmann T.
Cholesterol, A beta and Alzheimer's disease.
Trends Neurosci.
2001;
24
45-48
-
16
Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt H -C, Riemenschneider M, De Deyn P -P. et al .
Improved discrimination of AD patients using beta-amyloid(l-42) and tau levels in CSF.
Neurology.
1999;
52
1555-1562
-
17
Hyman B -T, Van Horsen G -W, Damasio A -R, Barnes C -L.
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation.
Science.
1984;
225
1 168-1 170
-
18
Ignatius M -J, Shooter E -M, Pitas R -E, Mahley R -W.
Lipoprotein uptake by neuronal growth cones in vitro.
Science.
1987;
236
959-962
-
19
Tick H, Zornberg G -L, Tick S -S, Seshadri S, Drachman D -A.
Statins and the risk of dementia.
Lancet.
2000;
356
1627-1631
-
20
Jurevics H, Morell P.
Cholesterol for synthesis of myelin is made locally, not imported into brain.
JNeurochem.
1995;
64
895-901
-
21
Kempen H -J, Glatz J -F, Gevers Leuven J -A, van der Voort H -A, Katan M -B.
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
J LipidRes.
1988;
29
1149-1155
-
22
Kivipelto M, Helkala E -L, Laakso M -P, Hanninen T, Hallikainen M, Alhainen K. et al .
Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study.
BMJ.
2001;
322
1447-1451
-
23
Kojro E, Gimpl G, Lammich S, März W, Fahrenholz F.
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10.
Proc Natl Acad Sci USA.
2001;
98
5815-5820
-
24
Locatelli S, Lütjohann D, Schmidt H -H, Otto C, Beisiegel U, von Bergmann K.
Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain.
Arch Neurol.
2002;
59
213-216
-
25
Lund E -G, Guileyardo J -M, Russel D.
cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain.
Proc Natl Acad Sci USA.
1999;
96
7238-7243
-
26 Lütjohann D. Cholesterol Homeostasis in the Brain: Importance of 24S-Hydroxylation. Doctorial Thesis 1999; ISBN 91-628-3410-X
-
27
Lütjohann D, Björkhem I, Locatelli S, Dame C, Schmolling J, von Bergmann K. et al .
Cholesterol dynamics in the foetal and neonatal brain as reflected by circulatory levels of 24S-hydroxycholesterol.
ActaPaediatr.
2001;
90
652-657
-
28
Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén A, Diczfalusy U. et al .
Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation.
Proc Natl Acad Sci USA.
1996;
93
9799-9804
-
29
Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring R -D. et al .
Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients.
J Lipid Res.
2000;
41
195-198
-
30 Meaney S, Hassan M, Sakinis A, Lütjohann D, von Bergmann K, Diczfalusy U. et al .Evidence that the major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res 2001: 42
-
31
Meaney S, Lütjohann D, Diczfalusy U, Björkhem I.
Formation of oxysterols from different pools of cholesterol as studied by stable isotope technique: cerebral origin of most circulating 24S-hydroxycholesterol in rats, but not in mice.
Biochim Biophys Acta.
2000;
1486
293-298
-
32
Notkola I -L, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P. et al .
Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease.
Neuroepidemiology.
1998;
17
14-20
-
33
Ose L, Davidson M -H, Stein E -A, Kastelein J -J, Scott R -S, Hunninghake D -B. et al .
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Clin Cardiol.
2000;
23
39-46
-
34
Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R. et al .
24S-Hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia.
J Psychiatr Res.
2002;
36
7-32
-
35
Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao M. et al .
Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer’s disease.
Neuroreport.
2000;
11
1959-1962
-
36
Pitas R -E, Boyles J -K, Lee H -E, Foss D, Mahley R -W.
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins.
Biochim Biophys Acta.
1987;
917
148-161
-
37
Rockwood K, Kirkland S, Hogan D -B, MacKnight C, Merry H, Verreault R. et al .
Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.
ArchNeurol.
2002;
59
223-227
-
38
Saunders A -M, Strittmatter W -J, Schmechel D, George-Hyslop P -H, Pericak- Vance M -A, Too S -H. et al .
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease [see comments].
Neurology.
1993;
43
1467-1472
-
39
Schmechel D -E, Saunders A -M, Strittmatter W -J, Grain B -J, Hulette C -M, Too S -H. et al .
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer’s disease.
Proc Natl Acad Sci USA.
1993;
90
9649-9653
-
40
Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, Beyreuther K . et al .
Cerebrospinal fluid 24S-Hydroxycholesterol is increased in Alzheimer’s disease compared to healthy controls.
Neurosci Letters.
2002;
324
83-85
-
41
Selkoe D -J.
Alzheimer’s disease: genes, proteins, and therapy.
Physiol Rev.
2001;
81
741-766
-
42
Simons M, Keller P, De Strooper B, Beyreuther K, Dottì C -G, Simons K.
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons.
Proc Natl Acad Sci USA.
1998;
95
6460-6464
-
43
Simons M, Keller P, Dichgans J, Schulz J -B.
Cholesterol and Alzheimer’s disease: is there a link?.
Neurology.
2001;
57
1089-1093
-
44
Simons M, Schwärzler F, Lütjohann D, von Bergmann K, Beyreuther K, Dichgans J. et al .
Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double- blind trial.
Ann Neurol.
2002;
52
346-350
-
45
Strittmatter W -J, Saunders A -M, Schmechel D, Pericak- Vance M, Enghild J, Salvesen G -S. et al .
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease.
Proc Natl Acad Sci USA.
1993;
90
1977-1981
-
46
Strittmatter W -J, Saunders A -M, Schmechel D, Pericak- Vance M, Enghild J, Salvesen G -S. et al .
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer’s disease.
Proc Natl Acad Sci USA.
1993;
90
1977-1981
-
47
Theunissen J -J, Jackson R -L, Kempen H -J, Demel R -A.
Membrane properties of oxysterols. Interfacial orientation, influence on membrane permeability and redistribution between membranes.
Biochim Biophys Acta.
1986;
860
66-74
-
48
Wolozin B.
A fluid connection: Cholesterol and Abeta.
Proc Natl Acad Sci USA.
2001;
98
5371-5373
-
49
Wolozin B, Kellman W, Ruosseau P, Celesia G -G, Siegel G.
Decreased prevalence of Alzheimer’s disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Arch Neurol.
2000;
57
1439-1443
Dieter Lütjohann, PhD
Department of Clinical Pharmacology
University of Bonn
Sigmund-Freud Str. 25
53105 Bonn
Germany
Phone: +49-228-2876080
Fax: +49-228-2876094
Email: d.luetjohann@uni-bonn.de
